BOSTON — Alloy Therapeutics said it has successfully completed an antibody discovery collaboration with Mediar Therapeutics, accelerating Mediar’s development timeline and enabling the company to advance new fibrosis programs into clinical development ahead of schedule.
Alloy, a biotechnology ecosystem company focused on expanding access to advanced drug discovery technologies, said the collaboration leveraged its ATX-Gx human transgenic mouse platform, advanced genetic immunization strategies, and AI- and machine learning-enabled discovery workflows. The effort resulted in a series of differentiated antibody binders against a challenging new target, allowing Mediar to move high-quality assets into IND-enabling studies more quickly than anticipated.
Following completion of the discovery campaign and the accelerated transition into IND-enabling work, Mediar closed an oversubscribed Series B financing, highlighting continued momentum in its efforts to develop novel therapies for fibrotic diseases.
“Mediar’s team set an ambitious goal to tackle a complex and challenging new target, and Alloy’s expertise enabled us to execute our discovery strategy efficiently and effectively,” said Rahul Ballal, Ph.D., chief executive officer of Mediar Therapeutics. “This collaboration has allowed us to advance multiple discovery programs into the clinic, ultimately bringing us closer to improving outcomes for patients.”
Alloy and Mediar have previously worked together on research that informed MTX-463, Mediar’s lead drug candidate currently in Phase 2 clinical development for idiopathic pulmonary fibrosis. For the latest project, Alloy generated panels of antibodies with strong target selectivity, cross-species reactivity, and favorable developability profiles, enabling Mediar to advance candidates into downstream development approximately six months earlier than expected.
“This collaboration reflects what we aim to do every day at Alloy: help partners move faster against hard biology,” said Errik Anderson, chief executive officer and founder of Alloy Therapeutics. “By pairing advanced discovery platforms with a deeply execution-focused, partner-first model, we’re supporting teams like Mediar as they push promising therapies closer to the patients who need them most.” (Source: IANS)
